Currently most statistical summaries of drug safety from clinical trials are displayed in lengthy tables or listings. It is a challenging for both reviewers and decision makers to use these presentations to quickly identify safety signals, to adequately characterize the drug safety profile in the context of their intended indication, and ultimately to make decisions regarding benefits and risks. The purpose of this presentation is to document the most frequently encountered clinical questions in reviewing safety data, as well as to recommend a set of graphics that were developed by representatives of the Industry/FDA/Academia Safety Graphics Working Group to address these questions and communicate important safety information more effectively and efficiently.